Dr. Elisabeth Roider

Elisabeth Roider, MD, Ph.D., MBA is Partner, Chief Scientific Officer and Chief Medical Officer at Maximon, a longevity company builder. As an Attending Physician and Principal Investigator, she works at the University Hospital Basel in Switzerland and as Lecturer and Investigator at the Harvard Medical School and Massachusetts General Hospital.

Elisabeth aims to allow people to achieve a long and healthy life by translating medical problems into scientifically-proven healthcare innovations and solutions.

As the Chief Scientific and Medical Officer at Maximon since 2022, she is eager to join the vision of building a global ecosystem of longevity companies. As a physician and scientist at heart, she is helping doctors and scientists address pressing medical and public health problems and transform innovation into solid business solutions. Read Elisabeth Roider joins Maximon as a Partner & Chief Scientific and Medical Officer and The Maximon Longevity Prize 2023: 50,000 CHF (56,000 USD).

Elisabeth has been leading a multidisciplinary, international team at Harvard Medical School since 2016 and since 2020 at the University Hospital Basel. With clinical trial specialists, biologists, chemists, machine learning specialists, mathematicians, statisticians, and epidemiologists, they aim towards an approach to solve complex, medical questions in the most efficient way. Read Biochemical pathway to skin darkening holds implications for prevention of skin cancers.

Her work has resulted in various high-impact publications, patents, and awards and is driven by the idea to identify relevant clinical problems, investigating them in a wet lab and a translational research setting, and validating them through clinical trials and studies. While her basic research focuses on novel mechanisms and solutions for medical prevention, cancer biology, and aging processes, it is her ultimate goal to bring innovation to the public to generate a benefit for our society.

Elisabeth is also at the Navarini Lab in the dermatology and allergy clinic at the University Hospital of Basel where she helped create DermaCompass, a web and mobile application that works as an assistant in Dermatology Practice.

At the University Hospital Basel, she is supervising students and postdocs and is doing research in basic and translational cell biology as well as running clinical trials.

Her private clinical work at Clinic Utoquai focuses on complex longevity-related medical problems and skin disorders. She creates and implements long-lasting, dermatological-aesthetic treatment concepts for the treatment of signs of aging. Her medical approach focuses on the treatment of obesity and hormonal changes, including hair loss, second opinion on complex, dermatological problems: systemic therapies for autoimmune diseases, as well as clarification, risk assessment, and treatment of skin cancer, infectious diseases, and pigment diseases. She also performs surgical dermatology for the treatment of skin cancer and cosmetically disturbing changes like full skin transplants.

Elisabeth earned her Doctor of Medicine (MD) in 2011 at the Ludwig-Maximilians-Univerität München. She earned her Ph.D. in Clinical Medicine in 2020 at Harvard University in collaboration with Szeged University with her thesis The cutaneous redox system as a driver of skin pigmentation and skin cancer risk. In 2021, Elisabeth earned her MBA from the University of St. Gallen.

Between 2011 and 2019, Elisabeth worked on and earned Board Certification in Dermatology (FMH and FEBDV). In 2017, she earned her Certificate in Good Clinical Practice in Medicine from the University of Zurich.

Elisabeth is a regularly invited speaker at Medical and Longevity conferences. In May of 2023, she spoke at the Longevity Biotech Conference in Zuzalu City in Montenegro. Elisabeth delivered valuable insights on longevity interventions and investing in Longevity Biotech. Watch Longevity Interventions — Which make sense and which don’t?

She spoke at the NIC International Conference 2023 in Singapore delivering a talk on Health Longevity for all: Democratising Longevity by bridging the gap between Science and Business innovation.

Elisabeth is on the Editorial Board of the Clinical & Experimental Dermatology and Therapies Journal.

Read Red Hair, Light Skin, and UV-Independent Risk for Melanoma Development in Humans and Mass. General-led study replicates tanning response in cultured human skin.

Visit her LinkedIn profile, her Online Doctor Profile, her Google Scholar page, and her ResearchGate profile. Follow her on Facebook, Instagram, and Twitter.